Drug Trial Radar · NCT05023525
A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Sep 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 28, 2021
Primary completion
Apr 19, 2022
Study completion Aug 16, 2022
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Haisco Pharmaceutical(Australia) Pty Ltd.
- First posted
- Aug 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, single-dose escalation clinical trial for HSK31858 conducted in healthy volunteers. The safety, tolerability, and pharmacokinetics of HSK31858 tablet in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design.
Conditions
- Healthy
Interventions
HSK31858, tabletDrug
Starting dose in single ascending dose: 5 mg
Placebo, tabletDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number and severity of treatment emergent adverse events (TEAEs)Time frame: 7 days after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.